Fifth Third Bancorp
CRVS icon

Fifth Third Bancorp’s Corvus Pharmaceuticals CRVS Stock Holding History

Fifth Third Bancorp’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.05K Buy
271
+250
+1,190% +$3.47K ﹤0.01% 3981
2026
Q1 		$307 Buy
+21
New +$335 ﹤0.01% 4223

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fifth Third Bancorp's CRVS Position: Q2 2026 in Review

Fifth Third Bancorp increased its Corvus Pharmaceuticals (CRVS) stake by 1,190% in Q2 2026, buying an estimated $3.47K and bringing the position to 271 shares worth $4.05K. The position accounts for ﹤0.01% of the portfolio, ranked #3981.

Fifth Third Bancorp first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Fifth Third Bancorp held 271 shares of Corvus Pharmaceuticals worth $4.05K as of Q2 2026.
  • Fifth Third Bancorp bought 250 Corvus Pharmaceuticals shares in Q2 2026, an estimated $3.47K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3981 holding.
  • Fifth Third Bancorp first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.